TO

TORII PHARMACEUTICAL CO., LTD.

A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.

4551 | T

Overview

Corporate Details

ISIN(s):
JP3635800000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目4番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Torii Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and marketing of ethical drugs. The company focuses its business activities on key therapeutic areas, including renal diseases and hemodialysis, skin diseases, and allergies. Its product portfolio addresses conditions such as atopic dermatitis and pruritus associated with chronic kidney disease. Following a tender offer completed in 2025, the company operates as a subsidiary of Shionogi & Co., Ltd.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-07 06:04
Registration Form
確認書
Japanese 9.3 KB
2025-08-07 06:01
Interim Report
半期報告書-第134期(2025/01/01-2025/12/31)
Japanese 215.6 KB
2025-07-10 08:30
Share Issue/Capital Change
臨時報告書
Japanese 215.5 KB
2025-06-19 02:04
Major Shareholding Notification
臨時報告書
Japanese 23.2 KB
2025-06-04 09:05
M&A Activity
訂正意見表明報告書
Japanese 171.8 KB
2025-05-08 08:56
Regulatory News Service
意見表明報告書
Japanese 373.9 KB
2025-03-31 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 24.8 KB
2025-03-27 07:23
Governance Information
内部統制報告書-第133期(2024/01/01-2024/12/31)
Japanese 24.0 KB
2025-03-27 07:22
Registration Form
確認書
Japanese 9.3 KB
2025-03-27 07:18
Annual Report
有価証券報告書-第133期(2024/01/01-2024/12/31)
Japanese 1.0 MB
2024-08-01 03:06
Interim Report
確認書
Japanese 9.2 KB
2024-08-01 03:05
Interim Report
半期報告書-第133期(2024/01/01-2024/12/31)
Japanese 187.0 KB
2024-04-26 08:07
Report Publication Announcement
確認書
Japanese 9.2 KB
2024-04-26 08:06
Quarterly Report
四半期報告書-第133期第1四半期(2024/01/01-2024/03/31)
Japanese 143.5 KB
2024-03-29 07:17
Post-Annual General Meeting Information
臨時報告書
Japanese 39.3 KB

Automate Your Workflow. Get a real-time feed of all TORII PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TORII PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TORII PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Upstream Bio, Inc. Logo
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
UroGen Pharma Ltd. Logo
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France
ALVAL
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
Vanda Pharmaceuticals Inc. Logo
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990
Vaxcyte, Inc. Logo
A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.
United States of America
PCVX
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom
VLG
Ventyx Biosciences, Inc. Logo
Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.
United States of America
VTYX
Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM

Talk to a Data Expert

Have a question? We'll get back to you promptly.